Non-Small Cell Lung Cancer
Advertisement
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Veterans with high socioeconomic deprivation experience suboptimal access to pre- and postoperative care for NSCLC.
Patients with NSCLC, treated with an immunotherapy regimen, have a higher risk of pneumonitis with decreased lung volume.
The approval is for certain patients with advanced, unresectable, or metastatic NSCLC with an NRG1 gene fusion.
An analysis of the CCTG BR.34 trial showed that bone metastasis correlated with worse outcomes in patients with NSCLC.
The study explored the relationship between sociodemographic disparities and access to minimally-invasive surgery for NSCLC.
Researchers evaluated the immunogenicity and safety of the COVID-19 vaccine in patients with lung cancer.
Detailed data from the trial will be presented at a medical meeting in 2025.
The recent report shows that the "breadth of tobacco-caused disparities continues to persist and expand."
The last Surgeon General’s report on tobacco-related disparities was released more than two decades ago in 1998.
A project led by a researcher from the Dana-Farber Cancer Center is the first to receive the four-year grant of $2.5 million.
Deborah Brown shares key findings from the recently released seventh annual "State of Lung Cancer" report.
Researchers Analyze Olaparib, Pemetrexed as Maintenance Therapy Additions to Pembrolizumab for NSCLC
Pembrolizumab plus maintenance olaparib was not shown to improve survival in patients with metastatic nonsquamous NSCLC.
The campaign kicked off on November 1 to coincide with Lung Cancer Awareness Month.
Durvalumab does not improve overall survival compared to chemotherapy when used as a first-line treatment for mNSCLC.
The updated analysis was presented at the Society for Immunotherapy in Cancer 2024 Annual Meeting.
Deborah Brown shares how the American Lung Association and its LUNG FORCE initiative are raising awareness this month.
Officials Provide Update on Datopotamab Deruxtecan Biologics License Application for NSCLC Treatment
A prior BLA has been voluntarily withdrawn and a new BLA has been submitted for US accelerated approval.
The real-world study is the first to provide an overview of EGFR mutations and subtype prevalence in patients with NSCLC.
Dr. Studts discusses why Lung Cancer Awareness Month is a critical time to inspire action, engagement, and hope.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.